About GRO Biosciences
GRO Biosciences is a private company based in Cambridge, Massachusetts. It has reported $33,290,111 raised in three offerings on Form D since August 2017. Its chief executive is Daniel Mandell.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 18, 2024 | Jul 25, 2024 | $27,440,115of $60.4M target | 13 | $2.1M | EquityRule 506(b) | Form D ↗ |
| Mar 14, 2019 | Mar 22, 2019 | $3,749,998fully sold | 10 | $374K | EquityRule 506(b) | Form D ↗ |
| Aug 16, 2017 | Aug 30, 2017amended Sep 21, 2017 | $2,099,998fully sold | 8 | $262K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, three offerings | $33,290,111 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on GRO Biosciences's Form D filed Jul 25, 2024.
BB
Bruce Beutel
Director
DB
Dan Becker
Director
TL
Tracey Lodie
Executive officer
KB
Kevin Bitterman
Director
DM
Daniel Mandell
Chief Executive Officer and director
RD
Rakhshita Dhar
Director
Earlier filings also listed Geoffrey Smith (director, last listed Mar 2019) and Christopher Gregg (director, last listed Mar 2019).